History

XINGIMAGING was founded in 2018 by Drs. Tamagnan, Chan, Marek and Seibyl, to create a unique clinical research company that combines excellence in clinical neurology/neuropsychiatry with state-of-art imaging using custom radiopharmaceuticals for diagnosis and monitoring of neurodegenerative and neuropsychiatric disorders. This fusion of internationally-recognized expertise in the clinical and imaging arenas into a unified research dedicated organization allows XingImaging to efficiently develop and execute clinical trials for diagnosis, progression and disease monitoring trials that emphasize quantitative imaging

outcome measures.

XingImaging LLC is a clinical PET imaging service company which offers end to end support of radiopharmaceutical imaging trials. XingImaging’s services include radioligand development, radioligand production, design and implementation of clinical imaging trials utilizing PET, and customized clinical imaging center coordination and management in multicenter imaging studies. 

XingImaging has two related business areas of expertise: 1) Translational Research - development and application of radioligands for both early drug development and/or to investigate disease pathobiology and 2) clinical multi-center imaging Core Lab services to apply radioligands in multi-center studies for subject eligibility and/or disease monitoring.

XingImaging has developed a highly efficient and focused translational research model for radioligand evaluation enabling us to rapidly and efficiently screen candidate radioligands moving promising radioligands from chemistry to pre-clinical and human proof of concept (POC) studies so that these radioligands may be applied to drug development or clinical questions. XingImaging has the expertise to offer radiochemistry support as needed both for its translational research studies and to ensure the quality of radiochemistry production and distribution in multi-center studies. XingImaging also provides comprehensive, coordinated, clinical research strategies for the application of imaging tracers in multi-center clinical trials.

In 2023,  XingImaging, and MITRO Biotech Co., Ltd. each highly recognized for drug development and imaging solutions joined forces to provide services across the pre-clinical and clinical spectrum including radioligand development and manufacturing, design and implementation of Phase 1 to Phase 4 clinical trials, and customized clinical imaging site coordination and management in multi-site imaging studies.